Pfizer

#AI #Biotechnology #Collaboration #Drug discovery #Pfizer

Pfizer and CytoReason collaborate to bolster AI in drug discovery

Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs.   Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. This deal which has the potential to be worth up… Read More

#Business & Investment #News

#BioNTech #Covid-19 #Moderna #Pfizer

Moderna sues Pfizer/BioNTech over Covid patent

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty… Read More

#Covid-19 #News

#Drug development #Immunology / Virology & Vaccines #Lyme Disease #Pfizer

Pfizer launches Phase III trial for Lyme disease vaccine  

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.   The Vaccine Against Lyme for Outdoor Recreationists (VALOR) trial will investigate the efficacy, safety and immunogenicity of Pfizer and Valneva’s Lyme disease vaccine… Read More

#News

#AstraZeneca #BioNTech #Covid-19 #Pfizer

Covid-19 vaccines remain effective six months after second dose

Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.  A study1 led by researchers at the University of Bristol found that two doses of Pfizer-BioNTech and AstraZeneca Covid-19 vaccines provided protection against Covid-19 infections six months… Read More

#Covid-19 #News

#BioNTech #Covid-19 #CureVac #mRNA #Pfizer

CureVac lawsuit against BioNTech over Covid-19 vaccine technology  

Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.  CureVac has filed the lawsuit in the German Regional Court in… Read More

#News

#Acquisition #GSK #Pfizer

A deal in the making

Listen to this article on the DDW Podcast: Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.  A number of recently announced deals by pharma companies has brought some excitement back into the sector after a rather stagnant period… Read More

#Business & Investment #Exclusive Content

#Acquisition #Biohaven #Migraine #Pfizer

Pfizer to buy Biohaven for $11.6bn

Pfizer is to acquire commercial-stage biopharmaceutical company Biohaven in a deal worth $11.6 billion. Biohaven is developing therapies for the treatment of migraine. The company’s lead product NURTEC ODT is a dual-acting migraine therapy which has been approved in the US for adult patients. The therapy has also been approved… Read More

#Business & Investment #News

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of… Read More

#News #Trending News #Trends & Analysis

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News

#Covid-19 #EMA #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer and BioNTech submit data for the vaccination of children 5 to 12 years 

Pfizer and BioNTech have submitted data supporting the vaccination of children 5 to 12 years of age with Comirnaty (Covid-19 mRNA vaccine) to the European Medicines Agency (EMA) for a variation of the Conditional Marketing Authorization (CMA) in the European Union (EU). According to The New York Times, federal regulators evaluated the… Read More

#News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

Health Canada approves Moderna, Pfizer and AstraZeneca vaccines 

Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria.  “Health Canada’s approval of our Covid-19 vaccine is an important milestone as it is our… Read More

#Covid-19 #News #Regulatory

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Pfizer

This week in drug discovery (23-27 August) 

News round-up by DDW’s Megan Thomas for 23-27 August  The Covid-19 pandemic has undoubtedly put virology back on the drug discovery map and this week, DDW’s Megan Thomas has rounded up five stories which show updates and advancements in the fight against the virus.  … Read More

#News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer #Regulatory

Full FDA approval for Pfizer-BioNTech Covid-19 vaccine 

The US Food and Drug Administration (FDA) has approved the Biologics License Application for the Pfizer-BioNTech Covid-19 vaccine. It will now be marketed as Comirnaty for the prevention of Covid-19 disease in individuals 16 years of age and older.  It is the first COVID-19 vaccine to be granted approval by the FDA.  The vaccine continues to… Read More

#Covid-19 #News #Trending News

Covid-19
#Clinical trials #Covid-19 #Immunotherapy #Moderna #mRNA #Pfizer

Study on third Covid-19 vaccine dose in kidney transplant recipients 

A pilot study has begun to assess the antibody response to a third dose of an authorised Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech Covid-19 vaccine. The Phase II trial is sponsored and funded by the National Institute of Allergy and… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Automation / robotics #Biopharmaceuticals #Covid-19 #CRISPR #Drug discovery #Immunology / Virology & Vaccines #Lab automation #Moderna #Molecular Biology #Pfizer #Sequencing

What has 2020 taught us about lab automation?

Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines… Read More

#Covid-19 #Exclusive Content #News